• Safety and Performance of the SPINEVISION Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease

  NCT06155409

  Active, not recruitingObservationalUpdated Mar 18, 2026
• Safety and Performance of the SpineVision Posterior Fixation Systems in Thoracolumbar Spinal Treatment

  NCT06342765

  RecruitingObservationalUpdated Mar 18, 2026
• An Evaluation of Interlaminar Lumbar Instrumented (ILIF™)

  NCT01019057

  CompletedObservationalUpdated Dec 24, 2025
• Efficacy and Safety of IntraSPINE® Associated With Discectomy in the Treatment of Lumbar Disc Herniation.

  NCT03752671

  CompletedInterventionalNot ApplicableUpdated Mar 20, 2025
• XLIF Decade Plate System Study

  NCT04689880

  CompletedObservationalUpdated Dec 22, 2025
• Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF)

  NCT01016314

  WithdrawnInterventionalNot ApplicableUpdated Jan 23, 2019

ClinicalTrials.gov ID

NCT05997121

Lead Sponsor

SPINEVISION SASINDUSTRY

Overall Status

Recruiting

Study Type

Observational

Enrollment

187Estimated

Last Update Posted

Mar 18, 2026Actual

Start Date

Jul 9, 2021Actual

Primary Completion Date

Oct 30, 2027Estimated

Completion Date

Oct 30, 2027Estimated

Official Title

Safety and Performance of the Hexanium TLIF System in the Treatment of Skeletally Mature Patients Suffering From Degenerative Disc Disease - Hexanium TLIF Study

Brief Summary

The goal of this observational study is to confirm the safety and efficacy of the Hexanium TLIF system in the treatment of skeletally mature patients suffering from degenerative disc disease (disease that occurs when the spinal disk break down).

Part of their standard of care, participants will be questioned on their back and leg pains, their disability and if they have encountered any adverse effects since the Hexanium TLIF system implant surgery. Those data will be collected up to twenty four (24) months after the Hexanium TLIF system implant surgery.

Detailed Description

The Hexanium TLIF study is a multicentric, international, ambispective, post market clinical follow-up study. This means that either subjects already implanted with the Hexanium TLIF system (retrospective subjects) or subjects planned for treatment with the Hexanium TLIF (prospective subjects) can be enrolled in the study.

Standard of care subjects data up to twenty four (24) months post Hexanium TLIF system implant procedure will be collected; key data include back and leg Visual Analogue Score (VAS), Oswestry Disability Index (ODI) score, and adverse events.

Data will be collected at Month 2, Month 6, Month 12 and Month 24 post surgery.

• Intervertebral Disc Degeneration

• Transforaminal lumbar interbody fusion

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No data available

Eligibility Criteria

Inclusion Criteria:

• Patient planned for Hexanium TLIF system implant or patient implant with Hexanium TLIF system (not prior to July 2021)
• Patient of 18 years old or more
• Patient has provided signed informed consent, or did not oppose to his/her data collection, per local regulation

Exclusion Criteria: contra-indication

• Infection, local to the operative site
• Signed of local inflammation
• Fever or leukocytosis
• Morbid obesity
• Pregnancy
• Paediatric cases, or patient still having general skeletal growth
• Spondylolisthesis unable to be reduced to Grade I
• Suspected or documented allergy or intolerance to metal
• Any case where the implant components selected for use would be too large or too small to achieve a successful result
• Any patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality
• Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance
• Prior fusion at the level to be treated
• Any case not needing a bone graft or fusion
• Any abnormality present which affects the normal process of bone remodelling including, but not limited to severe osteoporosis involving spine, bone absorption, osteopenia, primary or metastasis tumours involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis
• Any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumours or congenital abnormalities, fracture local to operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or marked left shift in the WBC differential count
• Mental illness
• Any patient unwilling to cooperate with post-operative instructions

Observational Model

Cohort

Time Perspective

Other

Lead Sponsor

SPINEVISION SASINDUSTRY

Collaborators

EVAMEDOTHER

mansouri.nz@gmail.com